PROVO, UT. (THECOUNT) — A high-profile capital murder case has been thrown into uncertainty following a “bombshell” court filing by defense attorneys for Tyler Robinson, the 22-year-old accused of fatally shooting conservative commentator Charlie Kirk.
Kirk was killed during a speaking engagement at Utah Valley University on September 10, 2025. While Robinson currently faces a potential death sentence, new forensic details suggest the prosecution’s case may be facing a significant evidentiary hurdle.
|
Advertisement |
The Missing Match
According to a motion filed on March 30, 2026, defense attorneys reveal that an official report from the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) was “unable to identify” the bullet recovered from Kirk’s autopsy as a match to the rifle allegedly tied to Robinson.
- The Weapon: Prosecutors previously linked Robinson to a vintage Mauser Model 98 rifle.
- The Conflict: The defense argues that this lack of a ballistic match creates reasonable doubt, stating the ATF could not definitively prove the fatal projectile was fired from that specific firearm.
The Prosecution’s Remaining Case
Despite this development, the State of Utah maintains it has a “mountain of evidence” against Robinson. Beyond the disputed ballistics, the prosecution is leaning on:
- DNA Evidence: DNA allegedly belonging to Robinson was found on the rifle’s trigger and a towel recovered near the scene.
- Digital Trail: Text messages sent by Robinson to his roommate and partner shortly after the shooting reportedly contain incriminating admissions.
- Eyewitnesses: Multiple individuals at the UVU event provided descriptions that investigators say led them directly to the suspect.
What Happens Next?
The defense is using the ATF report to request a delay in the preliminary hearing, originally scheduled for May 2026, to allow for independent forensic testing. The next major hurdle occurs on April 17, when a judge will rule on whether cameras will be permitted in the courtroom for what is expected to be one of the most-watched trials of the year.
DEVELOPING::